Company intelligence / Profile preview

Avlaan Pharma

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Avlaan Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing precision medicines for rare and life-threatening conditions. The company's lead program, AVL-001, is a small molecule antagonist of the ryanodine receptor 1 (RYR1), designed to treat disorders of calcium homeostasis. Avlaan is currently advancing AVL-001 through clinical trials for indications including Malignant Hyperthermia and Exertional Heat Stroke. By targeting the underlying pathophysiology of these critical conditions, the company aims to provide life-saving therapies where few options currently exist.

Therapeutic areas: OtherRare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Avlaan Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avlaan Pharma.

Explore the full profile